Nevertheless, DPP-4 inhibitors are still attractive second-line medications as they can be orally available, leading to increased patient compliance in T2D patients compared with GLP-1 receptor agonists which are administered by subcutaneous injection [31]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.